HCPCS Service Codes - Medical care

HCPCS Codes for Medical care

• M1319

  Patients who had documented contact with a csp for at least one of their screened positive hrsns within 60 days after screening

• M1320

  Patients who screened positive for at least 1 of the 5 hrsns

• M1321

  Patients who were not seen within 7 weeks following the date of injection for follow up or who did not have a documented iop or no plan of care documented if the iop was >25 mm hg

• M1322

  Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop =<25 mm hg for injected eye

• M1323

  Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of care was documented

• M1324

  Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant, or fluocinolone intravitreal implant)

• M1325

  Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or periocular steroid injection within the last six (6) months and had a subsequent iop evaluation with iop <25mm hg within seven (7) weeks of treatment)

• M1326

  Patients with a diagnosis of hypotony

• M1327

  Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeks

• M1328

  Patients with a diagnosis of acute vitreous hemorrhage

• M1329

  Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounter

• M1330

  Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)

• M1331

  Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial exam

• M1332

  Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeks

• M1333

  Acute vitreous hemorrhage

• M1334

  Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter

• M1335

  Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)

• M1336

  Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 2 weeks

• M1337

  Acute pvd

• M1338

  Patients who had follow-up assessment 30 to 180 days after the index assessment who did not demonstrate positive improvement or maintenance of functioning scores during the performance period

• M1339

  Patients who had follow-up assessment 30 to 180 days after the index assessment who demonstrated positive improvement or maintenance of functioning scores during the performance period

• M1340

  Index assessment completed using the 12-item whodas 2.0 or sds during the denominator identification period

• M1341

  Patients who did not have a follow-up assessment or did not have an assessment within 30 to 180 days after the index assessment during the performance period

• M1342

  Patients who died during the performance period

• M1343

  Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam or with excessive missing responses

• M1344

  Patients who did not have a baseline pam score and/or a second score within 4 to 12 months of baseline pam score

• M1345

  Patients who had a baseline pam score and a second score within 4 to 12 month of baseline pam score

• M1346

  Patients who did not have a net increase in pam score of at least 6 points within a 4 to 12 month period

• M1347

  Patients who achieved a net increase in pam score of at least 3 points in a 4 to 12 month period (passing)

• M1348

  Patients who achieved a net increase in pam score of at least 6-points in a 4 to 12 month period (excellent)

• M1349

  Patients who did not have a net increase in pam score of at least 3 points within a 4 to 12 month period

• M1350

  Patients who had a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter

• M1351

  Patients who had a suicide safety plan initiated, reviewed, or updated and reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation

• M1352

  Suicidal ideation and/or behavior symptoms based on the c-ssrs or equivalent assessment

• M1353

  Patients who did not have a completed suicide safety plan initiated, reviewed or updated in collaboration with their clinician (concurrent or within 24 hours) of the index clinical encounter

• M1354

  Patients who did not have a suicide safety plan initiated, reviewed, or updated or reviewed and updated in collaboration with the patient and their clinician concurrent or within 24 hours of clinical encounter and within 120 days after initiation

• M1355

  Suicide risk based on their clinician's evaluation or a clinician-rated tool

• M1356

  Patients who died during the measurement period

• M1357

  Patients who had a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment

• M1358

  Patients who did not have a reduction in suicidal ideation and/or behavior upon follow-up assessment within 120 days of index assessment

• M1359

  Index assessment during the denominator period when the suicidal ideation and/or behavior symptoms or increased suicide risk by clinician determination occurs and a non-zero c-ssrs score is obtained

• M1360

  Suicidal ideation and/or behavior symptoms based on the c-ssrs

• M1361

  Suicide risk based on their clinician's evaluation or a clinician-rated tool

• M1362

  Patients who died during the measurement period

• M1363

  Patients who did not have a follow-up assessment within 120 days of the index assessment

• M1364

  Calculated 10-year ascvd risk score of >= 20 percent during the performance period

• M1365

  Patient encounter during the performance period with hospice and palliative care specialty code 17

• M1366

  Focusing on women's health mips value pathway

• M1367

  Quality care for the treatment of ear, nose, and throat disorders mips value pathway

• M1368

  Prevention and treatment of infectious disorders including hepatitis c and hiv mips value pathway